MAPT and Alzheimer disease: Studies have shown that activation of NLRP3 inflammasome contributed to tau pathology and promoted Alzheimer’s disease progression, and inhibition of NLRP3 inflammasome with MCC950 improved cognitive decline after stroke in diabetic animals [21, 22, 36].